Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siplizumab Tolerance Induction in Liver Transplant
NCT06019507Phase 2Active, not recruiting
- Sponsor
- ITB-MED
- Start
- Jun 2022
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of siplizumab in Liver transplant rejection, sponsored by ITB-MED. Started Jun 2022; status: active, not recruiting.
02
Drugs
siplizumab
03
Conditions
Liver transplant rejection
Beyond the preview
Go deeper on NCT06019507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06019507.